Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Moskowitz

Showing results (161-170 of 280) with videos related to

Pageof 28
Sort By:
Leukemia & Lymphoma|July 16, 2005
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacyJeffrey L Halaas, Craig H Moskowitz, Steven Horwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicityBradford S Hoppe, Craig H Moskowitz, Daniel A Filippa, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2002
Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantationDorothy Pan, Craig H Moskowitz, Andrew D Zelenetz, et al.
British Journal of Haematology|December 17, 2016
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab eraSantosha A Vardhana, Craig S Sauter, Matthew J Matasar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to TransplantSantosha Vardhana, Paul A Hamlin, Joanna Yang, et al.
Radiology|June 3, 2015
Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive LymphomaGary A Ulaner, Debra A Goldman, Craig S Sauter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphomaC H Moskowitz, J R Glassman, D Wuest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2009
Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphomaR Schaffel, C V Hedvat, J Teruya-Feldstein, et al.
British Journal of Haematology|May 15, 2009
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaAlison J Moskowitz, Miguel-Angel Perales, Tarun Kewalramani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 2, 2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-IIOwen O'Connor, John Wright, Craig H Moskowitz, et al.
Pageof 28

Showing results (161-170 of 280) with videos related to

Sort By:
Pageof 28
Leukemia & Lymphoma|July 16, 2005
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacyJeffrey L Halaas, Craig H Moskowitz, Steven Horwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicityBradford S Hoppe, Craig H Moskowitz, Daniel A Filippa, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2002
Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantationDorothy Pan, Craig H Moskowitz, Andrew D Zelenetz, et al.
British Journal of Haematology|December 17, 2016
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab eraSantosha A Vardhana, Craig S Sauter, Matthew J Matasar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to TransplantSantosha Vardhana, Paul A Hamlin, Joanna Yang, et al.
Radiology|June 3, 2015
Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive LymphomaGary A Ulaner, Debra A Goldman, Craig S Sauter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphomaC H Moskowitz, J R Glassman, D Wuest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2009
Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphomaR Schaffel, C V Hedvat, J Teruya-Feldstein, et al.
British Journal of Haematology|May 15, 2009
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaAlison J Moskowitz, Miguel-Angel Perales, Tarun Kewalramani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 2, 2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-IIOwen O'Connor, John Wright, Craig H Moskowitz, et al.
Pageof 28